Literature DB >> 22347702

Censoring in survival analysis: Potential for bias.

Priya Ranganathan1, C S Pramesh.   

Abstract

Entities:  

Year:  2012        PMID: 22347702      PMCID: PMC3275994          DOI: 10.4103/2229-3485.92307

Source DB:  PubMed          Journal:  Perspect Clin Res        ISSN: 2229-3485


× No keyword cloud information.
Sir, We read with interest the article by Singh and Mukhopadhyay[1] on survival analysis. We commend the authors for simplifying a complex topic and for their in-depth explanation of the principles of survival analysis. However, the authors have failed to adequately emphasize one of the most important assumptions of censoring – which is that the censored patients are considered to have survival prospects similar to the participants who continued to be followed.[2] Censoring in survival analysis should be “non-informative,” i.e. participants who drop out of the study should do so due to reasons unrelated to the study. Informative censoring occurs when participants are lost to follow-up due to reasons related to the study, e.g. in a study comparing disease-free survival after two treatments for cancer, the control arm may be ineffective, leading to more recurrences and patients becoming too sick to follow-up. On the other hand, patients on the intervention arm may be completely cured by an effective treatment and may no longer feel the need to follow-up. If these participants are routinely censored, the true treatment effect will not be picked up and the results of the study will be biased. Disease-free survival rates would be based on the patients who continued to be followed-up in the study, and would be overestimated for the control arm and underestimated for the treatment arm. Several methods have been described to deal with the problem of informative censoring. These include imputation techniques for missing data, sensitivity analyses to mimic best and worst-case scenarios and use of the drop-out event as a study end-point.[3] For unbiased analysis of survival curves, it is essential that censoring due to loss to follow-up should be minimal and truly “non-informative.” Failure to understand these aspects of survival analysis could lead to grossly erroneous results from perfectly well-conducted studies.
  3 in total

Review 1.  Survival probabilities (the Kaplan-Meier method).

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1998-12-05

2.  Survival analysis in clinical trials: Basics and must know areas.

Authors:  Ritesh Singh; Keshab Mukhopadhyay
Journal:  Perspect Clin Res       Date:  2011-10

3.  Problems in dealing with missing data and informative censoring in clinical trials.

Authors:  Weichung Shih
Journal:  Curr Control Trials Cardiovasc Med       Date:  2002-01-08
  3 in total
  14 in total

1.  Simulation studies on the estimation of total area under the curve in the presence of right-tailed censoring.

Authors:  Peter L Bonate
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-31       Impact factor: 2.745

2.  A new comparison of nested case-control and case-cohort designs and methods.

Authors:  Ryung S Kim
Journal:  Eur J Epidemiol       Date:  2014-12-02       Impact factor: 8.082

3.  Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.

Authors:  Melany Garcia; Cailey McGillicuddy; Elisa M Rodriguez; Kristopher Attwood; Jennifer Schweitzer; Scott Coley; Denise Rokitka; Nicolas F Schlecht
Journal:  Pediatr Blood Cancer       Date:  2022-09-12       Impact factor: 3.838

4.  Association of ICU Admission and Outcomes in Sepsis and Acute Respiratory Failure.

Authors:  George L Anesi; Vincent X Liu; Marzana Chowdhury; Dylan S Small; Wei Wang; M Kit Delgado; Brian Bayes; Erich Dress; Gabriel J Escobar; Scott D Halpern
Journal:  Am J Respir Crit Care Med       Date:  2022-03-01       Impact factor: 30.528

5.  Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results.

Authors:  Richard F Potthoff
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

6.  Predictors of injecting cessation among a cohort of people who inject drugs in Tijuana, Mexico.

Authors:  Danielle Horyniak; Steffanie A Strathdee; Brooke S West; Meredith Meacham; Gudelia Rangel; Tommi L Gaines
Journal:  Drug Alcohol Depend       Date:  2018-02-21       Impact factor: 4.492

7.  Time-varying effects of prognostic factors associated with long-term survival in breast cancer.

Authors:  Minlu Zhang; Peng Peng; Kai Gu; Hui Cai; Guoyou Qin; Xiao Ou Shu; Pingping Bao
Journal:  Endocr Relat Cancer       Date:  2018-02-22       Impact factor: 5.678

8.  Short-term cessation of sex work and injection drug use: evidence from a recurrent event survival analysis.

Authors:  Tommi L Gaines; Lianne A Urada; Gustavo Martinez; Shira M Goldenberg; Gudelia Rangel; Elizabeth Reed; Thomas L Patterson; Steffanie A Strathdee
Journal:  Addict Behav       Date:  2015-01-19       Impact factor: 3.913

9.  Association of a Novel Index of Hospital Capacity Strain with Admission to Intensive Care Units.

Authors:  George L Anesi; Marzana Chowdhury; Dylan S Small; M Kit Delgado; Rachel Kohn; Brian Bayes; Wei Wang; Erich Dress; Gabriel J Escobar; Scott D Halpern; Vincent X Liu
Journal:  Ann Am Thorac Soc       Date:  2020-11

10.  Association of an Emergency Department-embedded Critical Care Unit with Hospital Outcomes and Intensive Care Unit Use.

Authors:  George L Anesi; Jayaram Chelluri; Zaffer A Qasim; Marzana Chowdhury; Rachel Kohn; Gary E Weissman; Brian Bayes; M Kit Delgado; Benjamin S Abella; Scott D Halpern; John C Greenwood
Journal:  Ann Am Thorac Soc       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.